Biologic characterization of the subcutaneously implanted Lewis lung tumor - PubMed (original) (raw)

• PMID: 4660735

Biologic characterization of the subcutaneously implanted Lewis lung tumor

J G Mayo. Cancer Chemother Rep 2. 1972 Nov.

No abstract available

PubMed Disclaimer

Similar articles

• Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.
  Mayo JG, Laster WR Jr, Andrews CM, Schabel FM Jr. Mayo JG, et al. Cancer Chemother Rep. 1972 Apr;56(2):183-95. Cancer Chemother Rep. 1972. PMID: 5043226 No abstract available.
• Effectiveness of clinically active antineoplastic drugs in a surgical-adjuvant chemotherapy treatment regimen using the Lewis Lung (LL) carcinoma.
  Merker PC, Wodinsky I, Cantor ML, Venditti JM. Merker PC, et al. Int J Cancer. 1978 Apr 15;21(4):482-9. doi: 10.1002/ijc.2910210414. Int J Cancer. 1978. PMID: 78911 No abstract available.
• Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.
  Griswold DP Jr. Griswold DP Jr. Cancer Chemother Rep 2. 1972 Nov;3(1):315-24. Cancer Chemother Rep 2. 1972. PMID: 4660734 No abstract available.
• 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
  Carter SK, Schabel FM Jr, Broder LE, Johnston TP. Carter SK, et al. Adv Cancer Res. 1972;16:273-332. doi: 10.1016/s0065-230x(08)60343-7. Adv Cancer Res. 1972. PMID: 4563045 Review. No abstract available.
• Biochemical aspects of drug combinations.
  Brockman RW. Brockman RW. Cancer Chemother Rep 2. 1974 Mar;4(1):115-29. Cancer Chemother Rep 2. 1974. PMID: 4135108 Review. No abstract available.

Cited by

• The Macrophage Activator GcMAF-RF Enhances the Antitumor Effect of Karanahan Technology through Induction of M2-M1 Macrophage Reprogramming.
  Ruzanova VS, Kirikovich SS, Levites EV, Proskurina AS, Dolgova EV, Ritter GS, Efremov YR, Dubatolova TD, Sysoev AV, Koleno DI, Ostanin AA, Chernykh ER, Bogachev SS. Ruzanova VS, et al. J Immunol Res. 2024 Feb 29;2024:7484490. doi: 10.1155/2024/7484490. eCollection 2024. J Immunol Res. 2024. PMID: 38455363 Free PMC article.
• Sex Differences in Lung Cancer.
  May L, Shows K, Nana-Sinkam P, Li H, Landry JW. May L, et al. Cancers (Basel). 2023 Jun 8;15(12):3111. doi: 10.3390/cancers15123111. Cancers (Basel). 2023. PMID: 37370722 Free PMC article. Review.
• A novel orthotopic mouse model replicates human lung cancer cachexia.
  van de Worp WRPH, Theys J, González AS, van der Heyden B, Verhaegen F, Hauser D, Caiment F, Smeets HJM, Schols AMWJ, van Helvoort A, Langen RCJ. van de Worp WRPH, et al. J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1410-1423. doi: 10.1002/jcsm.13222. Epub 2023 Apr 6. J Cachexia Sarcopenia Muscle. 2023. PMID: 37025071 Free PMC article.
• Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.
  Ruzanova V, Proskurina A, Efremov Y, Kirikovich S, Ritter G, Levites E, Dolgova E, Potter E, Babaeva O, Sidorov S, Taranov O, Ostanin A, Chernykh E, Bogachev S. Ruzanova V, et al. Pathol Oncol Res. 2022 May 27;28:1610180. doi: 10.3389/pore.2022.1610180. eCollection 2022. Pathol Oncol Res. 2022. PMID: 35693632 Free PMC article.
• Stopping transformed cancer cell growth by rigidity sensing.
  Yang B, Wolfenson H, Chung VY, Nakazawa N, Liu S, Hu J, Huang RY, Sheetz MP. Yang B, et al. Nat Mater. 2020 Feb;19(2):239-250. doi: 10.1038/s41563-019-0507-0. Epub 2019 Oct 28. Nat Mater. 2020. PMID: 31659296 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations